The story
In 1996, doctors learned that combining three anti-HIV drugs could suppress the virus to levels that blood tests could not detect. The key was adding a protease inhibitor, a drug that blocks the enzyme HIV uses to cut its proteins into working pieces, to two older drugs that blocked another viral enzyme, reverse transcriptase. The first protease inhibitor, saquinavir, was approved in December 1995, followed by ritonavir and indinavir in March 1996. At the International AIDS Conference in Vancouver in July 1996, the results of the combination treatments were presented as a turning point, and the regimen came to be called highly active antiretroviral therapy (HAART).
The earlier drug, AZT, approved in 1987, had slowed the disease only briefly because HIV mutates so quickly that resistance appears within months when a single drug is used. In 1995, David Ho in New York and George Shaw showed that the virus replicates furiously in every infected person, and new tests of the amount of virus in the blood (viral load) allowed them to measure whether treatment was working. If three drugs attacked at once, the odds of a virus mutating to resist all of them were very small.
The effect on patients was dramatic. In the United States, deaths from AIDS fell by more than 60 percent between 1995 and 1998, and patients who had been expected to die within months returned to work. The pills had strict schedules and cost roughly 10,000 to 15,000 dollars a year, so for years almost no one in Africa, where the epidemic was worst, could afford them. Generic manufacturers such as the Indian company Cipla began offering cheaper versions around 2001, and treatment access expanded through programs like PEPFAR. Modern regimens often combine drugs in a single daily pill, and people on treatment with undetectable virus do not pass HIV to partners.
Why it mattered
- PEPFAR, launched in 2003, was created to bring this therapy to millions in Africa and elsewhere.
- Generic drug competition and global pressure over patents pushed prices down by more than 95 percent in the early 2000s.
- Antiretroviral treatment became the basis of prevention, as people with suppressed virus do not transmit it and pre-exposure drugs can protect uninfected people.
- The combination-therapy approach became a model for treating other fast-mutating diseases, such as hepatitis C and tuberculosis.
Sources
- Timeline of the HIV and AIDS Epidemic HIV.gov
- CDC Newsroom: AIDS deaths decline (Aug 1999) CDC
- HIV treatment and research Mass General Brigham
Drafted by AI (Claude) from the sources above and checked against them by AI; no historian has reviewed this page. Spot a mistake? Suggest a correction. How pages are made
Community notes
Loading notes…